Literature DB >> 25788185

A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.

Wah-Kheong Chan1, Nik Raihan Nik Mustapha2, Sanjiv Mahadeva3.   

Abstract

BACKGROUND: The non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) is indeterminate in a proportion of NAFLD patients. Combining the NFS with liver stiffness measurement (LSM) may improve prediction of advanced fibrosis. We aim to evaluate the NFS and LSM in predicting advanced fibrosis in NAFLD patients.
METHODS: The NFS was calculated and LSM obtained for consecutive adult NAFLD patients scheduled for liver biopsy. The accuracy of predicting advanced fibrosis using either modality and in combination were assessed. An algorithm combining the NFS and LSM was developed from a training cohort and subsequently tested in a validation cohort.
RESULTS: There were 101 and 46 patients in the training and validation cohort, respectively. In the training cohort, the percentages of misclassifications using the NFS alone, LSM alone, LSM alone (with grey zone), both tests for all patients and a 2-step approach using LSM only for patients with indeterminate and high NFS were 5.0, 28.7, 2.0, 2.0 and 4.0 %, respectively. The percentages of patients requiring liver biopsy were 30.7, 0, 36.6, 36.6 and 18.8 %, respectively. In the validation cohort, the percentages of misclassifications were 8.7, 28.3, 2.2, 2.2 and 8.7 %, respectively. The percentages of patients requiring liver biopsy were 28.3, 0, 41.3, 43.5 and 19.6 %, respectively.
CONCLUSIONS: The novel 2-step approach further reduced the number of patients requiring a liver biopsy whilst maintaining the accuracy to predict advanced fibrosis. The combination of NFS and LSM for all patients provided no apparent advantage over using either of the tests alone.

Entities:  

Keywords:  Fibroscan; Liver fibrosis; Liver stiffness measurement; NAFLD fibrosis score; Non-alcoholic fatty liver disease (NAFLD); Non-invasive test

Mesh:

Year:  2014        PMID: 25788185     DOI: 10.1007/s12072-014-9596-7

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  22 in total

1.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

2.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

3.  Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.

Authors:  Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Angel Mei-Ling Chim; Ada Mei-Ling Tse; Steven Woon-Choy Tsang; Alex Yui Hui; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Wing-Yee So; Francis Ka-Leung Chan; Joseph Jao-Yao Sung; Henry Lik-Yuen Chan
Journal:  Am J Gastroenterol       Date:  2008-07-04       Impact factor: 10.864

4.  The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Salvatore Petta; Ester Vanni; Elisabetta Bugianesi; Vito Di Marco; Calogero Cammà; Daniela Cabibi; Lavinia Mezzabotta; Antonio Craxì
Journal:  Liver Int       Date:  2014-05-20       Impact factor: 5.828

5.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

Authors:  Laurent Castéra; Julien Vergniol; Juliette Foucher; Brigitte Le Bail; Elise Chanteloup; Maud Haaser; Monique Darriet; Patrice Couzigou; Victor De Lédinghen
Journal:  Gastroenterology       Date:  2005-02       Impact factor: 22.682

6.  Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease.

Authors:  Sanjiv Mahadeva; Anis Shafina Mahfudz; Anushya Vijayanathan; Khean-Lee Goh; Arumugam Kulenthran; Phaik-Leng Cheah
Journal:  J Dig Dis       Date:  2013-11       Impact factor: 2.325

7.  A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C.

Authors:  Jérôme Boursier; Victor de Ledinghen; Jean-Pierre Zarski; Marie-Christine Rousselet; Nathalie Sturm; Juliette Foucher; Vincent Leroy; Isabelle Fouchard-Hubert; Sandrine Bertrais; Yves Gallois; Frédéric Oberti; Nina Dib; Paul Calès
Journal:  Am J Gastroenterol       Date:  2011-04-05       Impact factor: 10.864

8.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

9.  The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD.

Authors:  Paul Angulo; Jason M Hui; Giulio Marchesini; Ellisabetta Bugianesi; Jacob George; Geoffrey C Farrell; Felicity Enders; Sushma Saksena; Alastair D Burt; John P Bida; Keith Lindor; Schuyler O Sanderson; Marco Lenzi; Leon A Adams; James Kench; Terry M Therneau; Christopher P Day
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

10.  Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations.

Authors:  Z M Younossi; T Gramlich; Y C Liu; C Matteoni; M Petrelli; J Goldblum; L Rybicki; A J McCullough
Journal:  Mod Pathol       Date:  1998-06       Impact factor: 7.842

View more
  13 in total

1.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

2.  Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan
Journal:  Hepatol Int       Date:  2015-03-11       Impact factor: 6.047

Review 3.  Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Authors:  Elliot B Tapper; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-02-21       Impact factor: 46.802

4.  Association between non-alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community.

Authors:  Eugene Choon-Li Tan; Mei-Ling Sharon Tai; Wah-Kheong Chan; Sanjiv Mahadeva
Journal:  JGH Open       Date:  2018-12-30

5.  Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study.

Authors:  Feng Gao; Kenneth I Zheng; Sui-Dan Chen; Dong Hyeon Lee; Xi-Xi Wu; Xiao-Dong Wang; Giovanni Targher; Christopher D Byrne; Yong-Ping Chen; Won Kim; Ming-Hua Zheng
Journal:  Clin Transl Gastroenterol       Date:  2021-03-10       Impact factor: 4.396

6.  Determination of "indeterminate score" measurements in lean nonalcoholic fatty liver disease patients from western Saudi Arabia.

Authors:  Yasir Mohammed Khayyat
Journal:  World J Hepatol       Date:  2021-12-27

7.  Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Wei-Yu Kao; I-Wei Chang; Chi-Long Chen; Chien-Wei Su; Sheng Uei Fang; Jui-Hsiang Tang; Chun-Chao Chang; Yu-Jia Chang; Weu Wang
Journal:  Obes Surg       Date:  2020-04       Impact factor: 4.129

Review 8.  Elastography Techniques for the Assessment of Liver Fibrosis in Non-Alcoholic Fatty Liver Disease.

Authors:  Yasushi Honda; Masato Yoneda; Kento Imajo; Atsushi Nakajima
Journal:  Int J Mol Sci       Date:  2020-06-05       Impact factor: 5.923

9.  Whole-liver histogram and texture analysis on T1 maps improves the risk stratification of advanced fibrosis in NAFLD.

Authors:  Xinxin Xu; Hong Zhu; Ruokun Li; Huimin Lin; Robert Grimm; Caixia Fu; Fuhua Yan
Journal:  Eur Radiol       Date:  2020-09-08       Impact factor: 5.315

10.  Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis.

Authors:  Hideki Fujii; Masaru Enomoto; Shinya Fukumoto; Tatsuo Kimura; Yuji Nadatani; Shingo Takashima; Atsushi Hagihara; Sawako Uchida-Kobayashi; Akihiro Tamori; Naoki Nishimoto; Norifumi Kawada
Journal:  JGH Open       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.